REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. To counter the ongoing decline in Eylea sales ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to "Neutral" from "Buy" given uncertainty ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...

Teva Pharmaceutical collaborates with Klinge Biopharma and Formycon AG to commercialize Formycon's biosimilar candidate to ...

If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Pharmaceuticals announced it will share corporate progress and highlights from the company’s investigational pipeline while ...

Investing.com -- Shares of Regeneron (NASDAQ: REGN) Pharmaceuticals (NASDAQ:REGN) fell 4% in premarket trading after the company reported lower-than-expected sales for a higher dose of its flagship ...